• English
  • Eesti

    Statistics on veterinary medicines

    27.03.2019
    Printer-friendly version

    Overview of Estonian Veterinary Medicinal Products Market

    Veterinary drug statistics is based on wholesaler’s reports. The statistics of veterinary medicinal products includes sales to general and veterinary pharmacies, veterinarians and to other institutions.

    WHOLESALERS

    In 2018 10 wholesalers sold veterinary medicines to general and veterinary pharmacies, veterinarians and to other institutions. As shown below two largest wholesalers covered over 83% and four largest wholesalers covered approximately 98% of the total veterinary medicinal products market and the share of the rest of wholesalers was modest.

    Wholesaler

    2014

    2015

    2016

    2017

    2018

    Zoovetvaru OÜ

    46.2%

    40.7%

    46.0%

    49.6%

    50.7%

    Magnum Veterinaaria AS

    26.2%

    29.0%

    29.4%

    29.8%

    32.2%

    Dimedium AS

     

    9.6%

    17.7%

    15.5%

    12.6%

    Optimer AS

    2.5%

    3.3%

    3.6%

    3.6%

    2.9%

    VETERINARY MEDICINAL PRODUCTS MARKET

    The veterinary medicinal products market is expressed in wholesale prices which includes the price of the manufacturer and wholesaler’s mark-up without the VAT.

    The veterinary medicinal products market increased 6-9% in years 2012-2014. In 2015 the total sales decreased 5%. Since 2016 the sales increased again compared to previous year respectively 7.8%, 8.0% and 13.3%, reaching in 2018 to 14.13 million euros.


    Figure 1. Estonian veterinary products market in 2014–2018

    VETERINARY MEDICINAL PRODUCTS MARKET SHARE

    Sales to the veterinary doctors or to the agricultural companies represented by veterinary doctor covered 87% (12.25 million euros) of the total veterinary medicinal products market in 2018. Almost 7% (0.97 million euros) of veterinary medicines were sold to the veterinary pharmacies and 5% (0.71 million euros) to the general pharmacies. Sales to the other institutions were 1% (0.20 million euros).


    Figure 2. Sales of veterinary medicinal products in 2014–2018

    VETERINARY MEDICINAL PRODUCTS MARKET SHARE BETWEEN ATCvet GROUPS

    Based on ATCvet classification three largest ATCvet groups covered 68% of total veterinary medicinal products market: antiinfectives 26.8% (3.79 million euros), antiparasitic products 20.6% (2.91 million euros) and  immunologicals 20.4% (2.88 million euros), followed by musculo-sceletal system (1.18 million euros), alimentary tract and metabolism (1.17 million euros) and genito urinary system and sex hormones (0.58 million euros). The rest of the ATCvet groups covered 11% of the total veterinary medicines market.


    Figure 3. Estonian veterinary medicinal products market share between ATCvet groups in 2016–2018

    ANTIINFECTIVES FOR SYSTEMIC USE

    Turnover of antiinfectives

    The turnover of antiinfectives increased until 2014, decreased considerable in 2015: compared to the previous year -19%, and stayed the same level in 2016–2017. In 2018 the turnover increased 16% compared to the previous year.

    The most sold antibacterials for systemic use by turnover were third-generation cephalosporins (QJ01DD), fluoroquinolones (QJ01MA) and penicillins with extended spectrum (QJ01CA). The turnover of pleuromutilins (QJ01XQ) had considerable increase in 2014 and 2018.


    Figure 4. Turnover of most sold antibacterials in 2014–2018

    The amount of sold antiinfectives by active ingredient

    The turnover of antibacterials increased 16% compared to the previous year, but the amount of sold active ingredients remained the same level compared to the year 2017 (6.5 tons in 2017 and 2018).


    Figure 5. The total amount of sold antibiotics in 2009–2018

    The most sold groups of antibiotics are penicillins, tetracyclines, pleuromutilins and aminoglucosides: in 2018 the share was respectively 33%, 21%, 16% and 7% of total antibacterials sold for veterinary use.


    Figure 6. Antibiotics for veterinary use in 2009–2018

    The most sold active ingredients in 2018 were Amoxicillin, Tiamulin, Doxycycline and Benzylpenicillin.

    Table 1. The most sold active ingredients (antibiotics) in 2009–2018 (sold in kilograms)

     

    Active ingredient

    2012

    2013

    2014

    2015

    2016

    2017

    2018

    1

    Amoxicillin

    1923

    2676

    2215

    2803

    2969

    1701

    1321

    2

    Tiamulin

    561

    512

    1827

    931

    728

    692

    1047

    3

    Doxycycline

    1474

    1460

    1875

    1577

    1526

    1380

    1042

    4

    Benzylpenicillin

    667

    737

    786

    679

    612

    683

    742

    5

    Dihydrostreptomycin

    534

    448

    392

    373

    343

    353

    339

    6

    Tylvalosin

    66

    61

    298

    161

    169

    180

    304

    7

    Oxytetracycline

    276

    239

    282

    386

    204

    178

    242

    8

    Sulfamethoxazole

    0

    150

    0

    0

    0

    205

    218

    9

    Sulfadiazine

    46

    49

    72

    64

    91

    90

    121

    10

    Spectinomycin

    180

    313

    466

    143

    42

    67

    114

    11

    Chlortetracycline

    57

    66

    66

    69

    103

    117

    111

    12

    Marbofloxacin

    26

    37

    46

    50

    75

    84

    93

    13

    Ceftiofur

    56

    66

    68

    63

    68

    76

    89

    14

    Paromomycin

    0

    0

    0

    12

    30

    43

    87

    15

    Colistin

    540

    697

    397

    137

    83

    109

    83

    ANTIPARASITIC PRODUCTS

    In the last ten years the turnover of antiparasitic products has been constantly increasing – more than twice in ten years, reaching 2.9 million euros in 2018.


    Figure 7. Turnover of antiparasitic products in 2014–2018

    IMMUNOLOGICALS

    In 2014–2018 the turnover of immunologicals remained between 2.5–2.9 million euros. 52% of immunologicals sold in 2018 were immunologicals for suidae.


    Figure 8. Turnover of immunologicals in 2014–2018

    HUMAN MEDICINES FOR VETERINARY USE

    In the absence of authorised veterinary medicine, veterinarian can use authorised human medicine if necessary. The most sold human medicines for veterinary use were drugs for sensory organs and nervous system, followed by drugs for blood and blood forming organs and antiinfectives for systemic use.


    Figure 9. Human medicines sales for veterinary use in 2018